http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101366365-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-167 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 |
| filingDate | 2010-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101366365-B1 |
| titleOfInvention | Controlled release pharmaceutical compositions comprising tramadol or a pharmaceutically acceptable salt thereof, and oral preparations comprising the same |
| abstract | The present invention relates to a pharmaceutical composition for controlled release, comprising tramadol or a pharmaceutically acceptable salt thereof as an active ingredient, and an oral preparation comprising the same. More specifically, it comprises a core containing a tramadol or a pharmaceutically acceptable salt thereof, and a plurality of microspheres including a release controlling polymer coating layer formed on the core, wherein the polymer composition of the release controlling polymer coating layer is the same. Pharmaceutical compositions comprising first and second microsphere groups that differ in average thickness; And an oral preparation containing the same. The pharmaceutical composition for controlling release according to the present invention can easily control the release pattern of the active ingredient in the gastrointestinal tract, thereby preventing the active ingredient from rapidly transitioning into the blood, thereby minimizing side effects, and reducing the effective blood concentration of the active ingredient. Not only can be maintained for a certain time, such as 12 hours or 24 hours, it can also mask the bitter taste for a certain time even when exposed in the oral cavity can increase the therapeutic effect for the patient when oral administration. |
| priorityDate | 2010-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.